Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
1.14 USD +2.70% Intraday chart for Lineage Cell Therapeutics, Inc. -0.87% +4.59%
11/03 Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting CI
07/03 Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury
Lineage Cell Therapeutics Launches $14 Million Registered Direct Offering
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Lineage Cell Therapeutics, Cancer Research UK Report 'Encouraging' Results in Lung Cancer Trial
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Lineage Cell Therapeutics, Inc. Announces Results from Imaging Analyses of Structural Changes and Visual Data from a Phase 1/2a Clinical Study of RG6501
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Lineage Enters into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
Lineage Cell Therapeutics, Inc. Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
Lineage Cell Therapeutics' Partner Genentech Launches Phase 2a Study of OpRegen
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. News Lineage Cell Therapeutics, Inc.
  5. Other languages